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Abstract: 
Many metastatic melanoma patients experience durable responses to anti-PD1 and/or anti-
CTLA4, however, a significant proportion (over 50%) do not benefit from the therapies. In 
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this study, we sought to assess pretreatment liquid biopsies for biomarkers that may correlate 
with response to checkpoint blockade. We measured the combinatorial diversity evenness of 
the T-cell receptor (TCR) repertoire (the DE50, with low values corresponding to more 
clonality and lack of TCR diversity) in pretreatment liquid biopsies from melanoma patients 
treated with anti-CTLA4 (n = 42) or anti-PD1 (n = 38) using a multi-N-plex PCR assay on 
genomic DNA (gDNA). A ROC curve determined the optimal threshold for a dichotomized 
analysis according to objective responses as defined by RECIST1.1. Correlations between 
treatment outcome, clinical variables, and DE50 were assessed in multivariate regression 
models and confirmed with Fisher exact tests. In samples obtained prior to treatment 
initiation, we showed that low DE50 values were predictive of a longer progression-free 
survival and good responses to PD-1 blockade, but on the other hand predicted a poor 
responses to CTLA4 inhibition.  Multivariate logistic regression models identified DE50 as the 
only independent predictive factor for response to anti-CTLA4 therapy (P = 0.03) and anti-
PD1 therapy (P = 0.001). Fisher exact tests confirmed the association of low DE50 with 
response in the anti-CTLA4 (P = 0.041) and the anti-PD1 cohort (P = 0.0016). Thus, the 
evaluation of basal TCR repertoire diversity in peripheral blood, using a PCR-based method, 
could help predict responses to anti-PD1 and anti-CTLA4 therapies. 
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Introduction: 
Despite durable objective responses (OR) seen with the FDA-approved immune checkpoint 
inhibitor (ICI) drugs anti-PD1 and anti-CTLA4, more than 50% of metastatic melanoma 
patients do not respond to these treatments (1). ICI therapies aim to modulate the immune 
system in order to enhance endogenous T-cell mediated anti-tumoral responses. This process 
allows patients to mount an immune response against the tumor with limited side effects. 
Thanks to the advent of those new therapies, in the last 6 years median survival increased 
from 9 months to 18 months (2). However, compared to previous treatments (i.e. targeted 
therapies), the mode of action of ICIs often lengthens the time until OR can be assessed. As a 
result, patients who do not respond to those therapies are potentially exposed to unnecessary 
side effects, are wasting precious time and may miss their treatment window. Even though 
few other therapeutic options currently exist, ongoing clinical trials (3-5) may produce a more 
diverse panel of treatments to choose from in the near future. Thus, a biomarker identifying 
patients who will respond to anti-PD1 or anti-CTLA4 monotherapies (or combination 
therapies) would help optimizing patients’ stratification in order to achieve the best possible 
therapeutic outcome given the available drugs. Since tumor-specific T cells present at the 
tumor site can also be found in the periphery in absence of metastasis (6,7), we hypothesized 
that the peripheral TCR repertoire could be used to detect clonal expansion of reactive T cells 
in melanoma patients. We used a PCR-based method to detect every possible V-J 
rearrangement in the CDR3 region of the TCRβ chain in peripheral blood samples from 
melanoma patients. The aim of this retrospective study was to assess whether the T-cell 
receptor (TCR) repertoire diversity evenness (DE50) before treatment initiation could predict 
which subpopulation of patients was more likely to respond to anti-PD1 or anti-CTLA4 
therapy. We showed that patients with a low DE50 score did not respond to anti-CTLA4 
treatment but did respond to anti-PD1 treatment. Thus, we demonstrated that the 
quantification of TCR repertoire diversity in the peripheral blood of melanoma patients, prior 
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to treatment initiation, could represent a predictive biomarker to guide the use of 
immunotherapies to the most appropriate patients. However, given the small size of our 
patient cohorts, these results need to be validated on a larger scale as well as in cohorts world-
wide before they can be applied in a clinical setting. 
 
Material and Methods 
Patients 
All experiments were carried out according to the Declaration of Helsinki principles after 
approval by the ethics committee (Swissethics, Kantonale Ethikkommission Zurich, vote 
number ZK.Nr.2014-0425). The study was performed on surplus material from two different 
cohorts of patients after having obtained written, informed consent approved by the local IRB 
(EK.647/800, KEK-ZH.2014-0425, N03LAM). The first cohort included 42 patients treated 
with anti-CTLA4 therapy, 18 were treated at the Netherlands Cancer Institute (NKI) and 24 at 
the University Hospital Zurich (USZ). Patients from the NKI were randomly assigned to the 
study whereas patients from USZ were selected to enrich the responder ratio. Additional 
clinical variables were collected around baseline (in a range of 30 days from treatment 
initiation). To harmonize the values of lactate dehydrogenase (LDH) between the two sites, 
LDH/upper limit of normal (480 U/l and 250U/l for UZH and NKI, respectively) was 
calculated. The second cohort was composed of 38 patients treated with anti-PD1 at the USZ. 
As for the CTLA4 cohort, absolute lymphocyte count (ALC), absolute neutrophil count 
(ANC), LDH, as well as S100 levels and leukocyte count were documented at baseline (all 
between -17 and +1 day from treatment start day, except for three LDH and eight S100 
concentrations, which were collected  between -42 days and + 27 days from the start of 
treatment when their values were stable over time). The OR was determined by Response 
Evaluation Criteria in Solid Tumors (RECIST1.1) after 12 weeks of treatment (average = 
11.28, median = 11.64, range = 4.7-17.7). Responders were classified as undergoing a 
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complete response (CR) or a partial response (PR) and non-responders were defined as stable 
disease (SD) or progressive disease (PD) state. Progression-free survival (PFS) represents the 
period between the treatment initiation to the date of progression or death, whichever 
occurred first. Patients’ characteristics are shown in Table 1. 
 
ImmunTraCkeR (Multiplex PCR assay) 
Peripheral blood mononuclear cell (PBMCs) from melanoma patients, prior to anti-CTLA4 (n 
= 42) or anti-PD1 (n = 38) treatment, were obtained by Ficoll-gradient centrifugation (Ficoll-
Paque Plus, GE healthcare). Genomic DNA was extracted from frozen PBMC samples using 
High Pure PCR Template Preparation Kit (Roche) and concentrated using Amicon ultra 0.5 
mL Centrifugal Filters (Millipore). ImmunTraCkeR
® 
(8), a TCR repertoire-profiling tool, was 
used to study the T-cell immune repertoire diversity based on the detection of V-J 
rearrangements of the CDR3 region of the TCRβ chain, as previously described (9). Briefly, 
multiplex PCR was performed using upstream primers specific for each V and downstream 
primer for each J segments; covering all the possible combinations (based on the international 
ImMunoGeneTics information system
®
, IMGT
®
, http://www.imgt.org). PCR products were 
separated by microfluidic migration (Labchip GX, Perkin Elmer) using a lab-on-a-chip (HT 
DNA 12 K LabChip Kit, Perkin Elmer). The PCR signals obtained were compared using 
Constel’ID®, a software that generates 3D maps representing the immune status of each 
patient. The diversity of the TCR pool was studied through the evenness of the repertoire 
based on frequencies of specific V-J rearrangements. For each patient, a diversity evenness 
score (DE50) was calculated as follow:  
 
𝐷𝐸50 =
𝑛𝑏 𝑟𝑒𝑎𝑟𝑟𝑎𝑛𝑔𝑒𝑚𝑒𝑛𝑡𝑠 𝑎𝑐𝑐𝑜𝑢𝑛𝑡𝑖𝑛𝑔 𝑓𝑜𝑟 50% 𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑝 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑜𝑡𝑎𝑙 𝑛𝑏 𝑟𝑒𝑎𝑟𝑟𝑎𝑛𝑔𝑒𝑚𝑒𝑛𝑡𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡
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A high score corresponds to a homogenous occurrence of each V-J rearrangement, whereas a 
low score represents a skew in the frequency towards specific rearrangements. Fig.1 shows 
the outline of the analysis pipeline. 
 
Statistical analysis 
The optimal thresholds for each variables were calculated by ROC analysis, using the Youden 
method (10) (OptimalCutpoints package in R).  
The relationship between OR and each biological/clinical variables was assessed in both 
cohorts, The prognostic factors, when available, were included in univariate logistic 
regression analysis with bias adjustment (Firth’s method (11)) using a previously ROC-
determined cut-off. Independent predictive variables of response were identified by a logistic 
regression analysis using a backward selection procedure. The added value of each selected 
variable in the models was evaluated using a penalized likelihood ratio chi-squared; 
likelihood scores of the model evaluated with and without the biomarker were compared, 
considering that lower likelihood scores will indicate better fitting models. The analyses 
including DE50 in the anti-PD1 cohort were performed using bias adjustment (Firth’s method 
(11)). The association between response and the high vs low DE50 group was assessed by a 
Fisher exact test. 
Relationship between PFS and the available biological/clinical variables was assessed by a 
univariate Cox proportional hazard regression model using the same previously ROC-
determined cut-offs. Independent predictive variables of PFS were identified by a multivariate 
Cox regression analysis using a backward selection procedure. The added value of each 
selected variable in the models was evaluated using a likelihood ratio test; likelihood scores of 
the model evaluated with and without the biomarker were compared, considering that lower 
likelihood scores will indicate better fitting models. For the Cox regression model assessing 
the correlation with PFS, NRAS mutation status was excluded from the backward selection 
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process because these data were missing too many pieces of information, which would limit 
the power of the test.  
Results of the regression models are presented in terms of β-coefficients. β-coefficients 
describe the change in the natural logarithm of the hazard ratio (HR) or odd ratio (OR) per 
unit of independent variable. (ℯ𝛽𝑐𝑜𝑒𝑓𝑓 = 𝐻𝑅 𝑜𝑟 𝑂𝑅) 
 
Results 
Multiplex PCR assay 
Diversity of the TCR repertoire was evaluated in a blinded fashion, using a multi-N-plex PCR 
assay, which measures combinatorial diversity between V and J genes of the β chain at the 
complementarity determining region 3 (CDR3), where most of the diversity is contained. In 
order to characterize the diversity of the repertoire, we calculated a diversity evenness score 
(DE50). The DE50 represents the ratio of the number of rearrangements among  the most 
frequent necessary to account for 50% of the global map intensity (cumulative sum of each 
rearrangement’s frequency) divided by the total number of rearrangements present. A TCR 
repertoire that is composed of an even frequency distribution of different V-J rearrangements 
is considered to have low clonality and thus a high DE50 score. A TCR repertoire that is 
dominated by some specific V-J rearrangements has a low DE50 and is considered to be more 
clonal. 
 
Patients and treatments 
In this retrospective study, baseline frozen PBMC samples from two separate cohorts of 
patients were analyzed. The first of the two cohorts included 42 metastatic melanoma patients 
who received ipilimumab at 3 mg/kg every 3 weeks, for a maximum of 4 infusions. Only 
patients who received at least 2 infusions were included. Absolute lymphocyte count (ALC), 
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absolute neutrophil count (ANC), and lactate dehydrogenase (LDH) levels were documented 
at baseline. 
The second cohort was composed of 38 patients treated with anti-PD1. 37 patients received 
pembrolizumab at 2mg/kg (or 10mg/kg for patients participating in the NCT01704287 study) 
every 3 weeks and 1 patient received nivolumab at 3mg/kg every 2 weeks. Patients who 
received fewer than 3 infusions were excluded from the analysis. The median follow-up was 
11.38 months (mean = 13.08) for patients who died and 32.75 months (median = 36.49) for 
patients who were still alive at the last follow-up. As for the CTLA4 cohort, ALC, ANC, 
LDH, as well as S100 levels, basophil, eosinophil and leukocyte counts were documented at 
baseline. We investigated the potential effect of prior treatment on each of the factors and 
outcome and found no correlation (Supplementary Fig. S1). Patients’ characteristics are 
shown in Table 1. 
The OR was determined by Response Evaluation Criteria in Solid Tumors (RECIST1.1) after 
at least 12 weeks of treatment (average = 11.28, median = 11.64, range = 4.7-17.7). We 
evaluated response according to objective response rate, that is complete response (CR) and 
partial response (PR) are considered to be responders and stable disease (SD) and PD are 
considered to be non-responders. Survival plots for PFS and overall survival (OS) are shown 
in Fig. 2. 
  
Analysis of pretreatment clinical parameters and correlation with response. 
Firstly, for each clinical parameter, an appropriate threshold for dichotomized analysis was 
determined by a receiver operating characteristic (ROC) curve. The optimal cutoff points 
separating responders from non-responders were calculated using the Youden method (10). 
Thresholds are shown next to the variables in each of the tests.  
To assess the predictive potential of DE50 and the different clinical variables on response to 
treatment, reliable prognostic factors were included in univariate logistic regression analysis 
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using previously ROC-determined cut-offs (Fig. 3). In the anti-CTLA4 treated cohort, only 
DE50 appears to be significant in the univariate model, and it is the only independent factor 
that is conserved in the multivariate model (Fig. 3A). Since the only outcome variable 
available for all the patients in this cohort was OR, no survival analysis could be performed. 
In the anti-PD1 treated cohort, at the univariate level, both LDH and DE50 are significantly 
correlated with response to treatment. To determine if the candidate predictive factors of our 
model were independent predictors of response, we performed a multivariate logistic 
regression analysis using a backward selection procedure. The best fitting model only 
identified DE50 as independent predictive factor (Fig. 3B).  
 
Correlation between baseline DE50 levels and response to treatment 
In order to identify the predictive potential of baseline TCR repertoire clonality and its 
association with clinical benefit, we analyzed the relationship between low and high DE50 and 
response to treatment (Fig. 4). In the anti-CTLA4 treated cohort, all the patients who had 
DE50 < 20.03% at baseline did not respond to the treatment (p = 0.041) (Fig. 4A). Conversely, 
in the anti-PD1 treated cohort, a baseline DE50 level below 20.4% was associated with good 
response to the treatment at 12 weeks (p = 0.0016) (Fig. 4B). 
 
Identification of clinical parameters linked with PFS in the anti-PD1 cohort 
Independent predictive variables of PFS were identified by a Cox regression analysis using 
the ROC determined cut-offs. The univariate model identified LDH (βcoeff = -0.945, 95%CI 
= -1.761- -0.129, P = 0.023) and S100 (βcoeff = -1.814, 95%CI = -3.027- -0.601, P = 0.003) 
as the only two variables significantly correlated with PFS (Fig. 5A). Backward selection 
procedure was used to extract the most explanatory variable for the multivariate model. The 
multivariate Cox regression for PFS retained DE50, ANC/ALC, ALC, and S100; only S100 
appears not to be an independent factor associated with PFS (p>0.05) (Fig. 5B). 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
11 
 
 
Discussion 
The approval of ICIs as first line treatment for melanoma (in 2011) and subsequent 
developments represent a huge improvement in cancer management. However, patients’ 
responses are still variable and unpredictable. Few reliable biomarkers are available in clinical 
practice to optimize patient selection and treatment efficacy for immunotherapy.  
The first candidate to be examined for anti-PD1 therapy was PD-L1. However, intratumoral 
PD-L1 expression failed as a predictive biomarker, since PD-L1 negative patients also 
responded to the treatment (12,13). This result may be explained by the lack of a standardized 
method of detection (different cut-offs and kits were used) or by the fact that the biopsy used 
for the assay does not account for the full tumor heterogeneity or the dynamic receptor 
expression (14). The other drawback inherent in PD-L1 or other tumor staining assay is the 
need for at least part of the tumor to be sampled, which requires an invasive procedure and 
may not be feasible due to the location of the tumor. Liquid biopsies derived from blood or 
serum avoid the problem of invasive procedures.  In the context of anti-PD1 treatment, some 
potential predictive markers have been tested in the peripheral blood, namely, LDH levels as 
well as eosinophil, monocyte and lymphocyte counts (15,16). In patients treated with anti-
CTLA4, studies have investigated lymphocyte, monocyte, eosinophil or neutrophil counts as 
predictive markers of patients’ responses (17-19). The results of those studies are 
contradictory, and  seems to hold more prognostic than predictive information (20,21). 
Furthermore, serum levels of C-reactive protein, LDH, soluble CD25 and VEGF have been 
associated with clinical outcome (22-24). Unfortunately, most of the analyses have been 
performed on small cohorts and none of these potential markers have been validated 
prospectively (25), except for very high LDH levels which is associated with poor prognosis 
in anti-CTLA4 treated patients (26). No predictive biomarker for patient stratification prior to 
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treatment other than routine PD-L1 staining (27) has yet proven robust enough to be used in 
the clinic. 
 
The efficacy of ICIs relies on the activation and effector functions of the adaptive immune 
system and largely on T cells. However, the exact mechanisms of action are not understood.  
Anti-CTLA4 was shown to lower the threshold for T-cell priming and therefore allow 
expansion of a higher number of effector T cells (28). Anti-CTLA4 also increases clonal 
expansion of memory T cells (29) and depletes regulatory T cells (Tregs) in the tumor micro-
environment (30) leading to an increase in the effector T-cell/Treg ratio at the tumor site (31). 
The major reported effect of PD1 blockade, in the context of cancer treatment, was the 
restoration of T-cell functions during the effector phase. Anti-PD1 was demonstrated to 
salvage exhausted CD8
+
 T cells, restoring their cytotoxic potential, leading to the destruction 
of tumor cells (32). Anti-PD1 was also reported to affect Treg differentiation and function by 
preventing PD1 ligation to PD-L1 on antigen presenting cells, which have been shown to play 
a key role in Treg’s development (33). However, PD1 has a broad expression pattern: it is 
expressed on T cells as well as B-cells, natural killer cells, dendritic cells, and myeloid cells. 
Its ligands, PD-L1 and PD-L2, are also expressed on various hematopoietic and non-
hematopoietic cells as well as cancer cells (34,35). As a result, anti-PD1 therapy can affect 
various cell types and pathways in ways still being investigated (36,37). More research is 
required to understand the exact modes of anti-CTLA4 and anti-PD1 action. Nevertheless, the 
effect of ICI therapies on the TCR repertoire has been intensively studied. Several groups 
have shown that anti-CTLA4 and anti-PD1 therapies reshape the TCR repertoire in different 
ways (38). Anti-CTLA4 broadens the T-cell repertoire, whereas anti-PD1 drives proliferation 
of a restricted number of clones, giving rise to a skewed peripheral repertoire . 
Anti-CTLA4 expands the peripheral TCR repertoire in a non-specific manner by inhibiting 
Tregs and increasing the CD8
+
/Treg ratio (39,40). Improved clinical outcome is associated 
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with reduced clonotype loss and maintenance of high-frequency clonotypes from the start and 
throughout treatment duration (41). This provides evidence that the baseline TCR repertoire 
profile might play a role in the response to the treatment. 
Investigation of the TCR repertoire in tumors demonstrated a positive association between the 
clonality of the intra-tumoral T-cell repertoire at baseline and response to anti-PD1 (42). 
Other groups confirmed those results and showed that anti-PD1 stimulates oligoclonal 
expansion of certain T-cell clones at the tumor site, in particular those that were present at a 
higher frequency (43,44). Altogether, these results suggest that the initial shape of the T-cell 
repertoire may guide therapeutic decisions. Other studies have analyzed the TCR repertoire 
using next-generation sequencing (NGS), however NGS approaches are currently too 
expensive and the data processing too time consuming for routine clinical use.  
Here we have aimed to develop a tool that could be useful in the clinic for routine patient 
stratification. The primary objective of this study was to determine whether baseline TCR 
repertoire diversity could be used as a predictive biomarker of response to anti-PD1 and anti-
CTLA4 and how it compares to other predictive variables described in the literature. 
In order to reduce the number of factors included in our analysis, we first confirmed that the 
previous treatments received by the patients did not affect the clinical variables and was not 
correlated with response (Supplementary Fig. S1). Then, to compare our predictor’s 
performance to other proposed markers in the literature, we performed regression analyses 
including other relevant factors whenever available. At the multivariate level, using the ROC 
determined threshold, DE50 was the only significant predictor of response in our cohorts. We 
also observed that in the univariate analyses, LDH level was significantly correlated with PFS 
and response to anti-PD1 therapy. Baseline LDH levels are thought to be indicative of future 
outcome irrespective of treatment (45-47), but can lead to false positive predictions of 
response. For instance, some patients with high baseline LDH levels can also achieve a good 
response to anti-PD1 (48) and high and low LDH groups show no difference in treatment 
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efficacy (49). This underscores the need to find better early predictors of response to ICI 
therapies. 
 
The only other factors able to independently predict outcome in one of our cohort were the 
neutrophil-to-lymphocyte ratio (ANC/ALC) and the ALC, which had PFS predictive power in 
anti-PD1 treated patients. ANC/ALC has already been shown to be a predictive marker for 
response in anti-PD1 treated melanoma patients (50). Because ANC/ALC is described as a 
prognostic factor which is also correlated with leukocyte/lymphocyte ratio (51), we 
investigated this potential association in our cohort (Supplementary Fig. S2). Indeed, we 
found a similar correlation. Patients with low ANC/ALC expression have more T-cell tumor 
infiltration compared to the high ANC/ALC group (51). This would support our results since 
T-cell infiltration is a key element for an appropriate immune response against the tumor. 
Nevertheless, other studies found a correlation between ANC/ALC and patient outcome 
regardless of the treatment (52,53). 
 
Overall, our analysis showed that ALC ≥ 1.27 G/l and ANC/ALC < 2.86 are correlated with 
longer PFS and are also associated with a high lymphocyte to leukocyte ratio. We showed that 
the detection of a basal clonal TCR repertoire characterized by DE50 < 20.4% in peripheral 
blood, via a conventional PCR based method, is able to predict response to anti-PD1 
treatment at 12 weeks. On the other hand, a clonal TCR repertoire prior to anti-CTLA4 
therapy characterized by DE50 < 20.03% is associated with poor response to the treatment. In 
line with our results, DE50 is also significantly correlated with PFS at 12 months 
(Supplementary Fig. S3A) and OS at 24 months (Supplementary Fig. S3B) in the anti-PD1 
cohort of patients. 
We have demonstrated that TCR repertoire clonality, represented by the TCR diversity index 
DE50, can help predict patient outcome under anti-PD1 and anti-CTLA4 therapy. A low DE50 
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(i.e. clonal repertoire) was associated with a poor response to anti-CTLA4 and with a better 
response and a longer PFS in patients treated with anti-PD1, which is consistent with 
previously published literature (9,54).  
Our results indicate that patients with a repertoire dominated by specific rearrangements may 
benefit more from anti-PD1. However, our analysis does not allow us to determine the exact 
composition of the TCR repertoire in terms of cell types nor to discriminate between pro-
tumorogenic (i.e. CD4
+
 Treg) and anti-tumorogenic cell types (i.e. cytotoxic CD8
+
). Yet, two 
hypothesis would support the rationale of our finding. Firstly, in patients whose immune 
system fails to eliminate the tumor, there is an increase in exhausted T cells (55). Those cells 
could correspond to the clonal expansion we detect at baseline and explain the subsequent 
efficient response to anti-PD1 treatment, which restores function to these tumor-specific T 
cells. Secondly, baseline T-cell repertoire of non-responders have a higher proportion of 
CD8
+
 naïve T cells, whereas responders have a larger population of central memory T cells 
(16). Hence, the higher clonality of the T-cell repertoire seen at baseline could also be due to a 
higher population of memory T cells, which respond particularly well to PD1 blockade (56). 
A clonally expanded TCR repertoire at baseline appears to preclude the efficacy of anti-
CTLA4 treatment. A skewed TCR repertoire is the representation of an immune system that is 
responding to a foreign invasion (57). If, prior to therapy initiation, the patient’s immune 
system has already mounted a response against specific antigens (here, we assume melanoma 
antigens), treatment with anti-CTLA4 will be of little use. Indeed, the therapy is mainly aimed 
at eliciting a T-cell response by sequestrating the receptor responsible for inhibition. This 
means that the treatment has little effect on already activated and expanded T-cell populations 
(58). If the T-cell clones present before therapy initiation were not able to keep the disease 
under control, anti-CTLA4 treatment will not improve the outcome. Furthermore, a highly 
clonal repertoire with no response is most likely associated with immune checkpoints up-
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regulation and T-cell exhaustion. In keeping with this assumption, anti-CTLA4 based 
treatment is ineffective on melanoma with high PD-L1 expression (40). 
Our data need to be further validated in a larger and independent cohort with similar inclusion 
criteria. Moreover, additional studies are necessary to assess the TCR specificity of the 
clonally expanded T cells in responding patients in order to determine which epitopes are 
being recognized. A limitation of our study is that we cannot demonstrate if the expanded 
clones that were identified in the responding patients were tumor specific. However, the fact 
that responders to anti-PD1 therapy showed substantial expansion of only a limited number of 
clones (Supplementary Fig. S4) would corroborate previous studies demonstrating that the 
anti-tumor response only relies on a restricted number of specific TCR (59,60). In summary, 
with this study we propose the analysis of peripheral blood TCR repertoire as a predictive tool 
to facilitate patient stratification in the context of ICI therapy for melanoma. 
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Table 1. Patient characteristics for anti-CTLA4 and anti_PD1 cohorts. N = number of patients in each 
category. % = representation in percent for each category. 
PATIENT CHARACTERISTICS 
Anti-PD1 Anti-CTLA4 
N % N % 
Age         
< 40 years old 2 5.3% 3 7.1% 
40-55 years old 11 28.9% 14 33.3% 
56-70 years old 14 36.8% 18 42.9% 
> 70 years old 11 28.9% 7 16.7% 
Gender         
Male 27 71.1% 23 54.8% 
Female 11 28.9% 19 45.2% 
Progression-free survival (PFS)         
< 3 months 9 23.7% 13 59.1% 
3-9 months 11 28.9% 6 27.3% 
> 9 months 18 47.4% 3 13.6% 
Recist 1.1 at ~12 weeks         
CR 1 2.6% 2 4.8% 
PR 11 28.9% 10 23.8% 
SD 12 31.6% 3 7.1% 
PD 14 36.8% 27 64.3% 
BRAF mutation status         
Wild type 27 73.0%     
Mutated 10 27.0%     
NRAS mutation status         
Wild type 21 60.0%     
Mutated 14 40.0%     
Previous treatments         
Chemotherapy 3 7.9%     
Targeted therapy 2 5.3%     
Immunotherapy (ipilimumab) 28 73.7%     
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Radiotherapy 4 10.5%     
Interferon 1 2.6%     
Lactate dehydrogenase (LDH/ULN)         
< 1 20 54.1% 27 67.5% 
≥ 1 17 45.9% 13 32.5% 
S100         
< 0.2 μg/l 10 27.8%     
≥ 0.2 μg/l 26 72.2%     
Absolute Neutrophil Count (ANC)         
< 8 G/l 35 92.1% 40 95.2% 
≥ 8 G/l 3 7.9% 2 4.8% 
Absolute Lymphocyte Count (ALC)         
< 1.5 G/l 25 65.8% 28 66.7% 
≥ 1.5 G/l 13 34.2% 14 33.3% 
Leukocytes         
< 9.6 G/l 34 89.5%     
≥ 9.6 G/l 4 10.5%     
Basophils         
< 0.15 G/l 20 52.6%     
≥ 0.15 G/l 18 47.4%     
Eosinophils         
< 0.7 G/l 36 94.7%     
≥ 0.7 G/l 2 5.3%     
 
 
 
 
 
Figure legends 
Fig. 1 Outline of analysis pipeline 
 
Fig. 2 Kaplan-Meier plots showing survival in R (responders) and NR (non-responders) 
to anti-PD1 treatment. Colored bands represent 95% confidence interval. A) PFS 
probability, B) OS probability. 
 
Fig. 3 Logistic regression model assessing the relationship between pretreatment clinical 
parameters (including DE50) and response to therapy. Forest plots and tables represent the 
β coefficients of the clinical variables that may affect response to treatment. Blue lines 
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represent the 95% confidence interval. A) Univariate analysis for the anti-CTLA4 treated 
cohort. * : DE50 is the only factor conserved in the multivariate analysis. B) Univariate 
analysis for the anti-PD1 treated cohort. * : DE50 is the only factor conserved in the 
multivariate analysis. In the multivariate analyses, factors were selected using a backward 
selection process. 
 
Fig. 4 TCR diversity evenness at baseline, prior to treatment. A) Dot plot showing DE50 at 
baseline in patients who eventually responded or did not respond to anti-CTLA4 therapy. N= 
42. Dashed line = 20.03%. B) Dot plot showing DE50 levels at baseline in patients who 
eventually responded or did not respond to anti-PD1 therapy. N= 38. Dashed line = 20.4%. P 
value calculated with Fisher exact test. 
 
Fig. 5 Cox regression model assessing correlation of clinical variables with PFS in the 
anti-PD1 cohort. Forest plots and tables represent the β coefficients of the clinical variables 
that may affect PFS. Blue lines represent the 95% confidence interval. A) Univariate analysis. 
B) Multivariate analysis using backward selection procedure. 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
Research. 
on November 15, 2018. © 2018 American Association for Cancercancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 13, 2018; DOI: 10.1158/2326-6066.CIR-18-0136 
